Table 1 Characteristics of the included studies

Year

2020

2021

2021

SGLT2 inhibitor agent

Empagliflozin

Sotagliflozin

Empagliflozin

Type of patients

Patients with acute heart failure regardless of diabetes status

Patients with acute heart failure and type 2 diabetes

Patients with acute heart failure regardless of diabetes status

Participants (N)

79

1,222

530

SGLT2 inhibitor group (N)

40

608

265

Placebo group (N)

39

614

265

Age, years (mean)

76

69

71

Women (%)

33%

34%

33%

Race

Empagliflozin group had 100% Whites, whereas placebo group had 95% Whites and 5% others

Sotagliflozin group had 93.3% Whites, 4.1% Blacks, and 1.3% Asians, whereas placebo group had 93.2% Whites, 4.1% Blacks, and 1.1% Asians

Not reported in the American Heart Association 2021 presentation

Diabetes

Empagliflozin group: 38%

Placebo group: 28%

100% in both groups

Empagliflozin group: 46.8%

Placebo group: 43.8%

Hypertension

Empagliflozin group: 68%

Placebo group: 56%

Not reported

Empagliflozin group: 77.4%

Placebo group: 83.4%

Myocardial infarction

Empagliflozin group: 30%

Placebo group: 38%

Not reported

Empagliflozin group: 24.9%

Placebo group: 23.4%

Beta-blocker use

Empagliflozin group: 70%

Placebo group: 66%

Sotagliflozin group: 92.8%

Placebo group: 91.4%

Not reported in the AHA presentation

ACEi use

Empagliflozin group: 40%

Placebo group: 47%

Sotagliflozin group: 41.8%

Placebo group: 39.3%

Not reported in the AHA presentation

ARB use

Empagliflozin group: 5%

Placebo group: 3%

Sotagliflozin group: 40.3%

Placebo group: 44%

Not reported in the AHA presentation

ARNI use

Empagliflozin group: 5%

Placebo group: 3%

Sotagliflozin group: 15.3%

Placebo group: 18.2%

Not reported in the AHA presentation

MRA use

Empagliflozin group: 48%

Placebo group: 45%

Sotagliflozin group: 66.3%

Placebo group: 62.7%

Not reported in the AHA presentation

Follow-up

60 days

9 months

90 days